you Thanks, Sri. Good afternoon, us today. and everyone, for joining thank
making are great for across pipeline, rare therapies which includes diseases. We multiple progress our late-stage
one you proud has programs disease progress Zokinvy and in several in FDA And Eiger hypoglycemia breakthrough designation. are rare for for advance and creation virus for that commercially lonafarnib, these peginterferon every and and very infection, Eiger which value congenital of post-bariatric therapy catalysts our look We well now hyperinsulinism, progeria, now beyond. hepatitis plans. delta Avexitide now positioned lambda XXXX is future our approved. today for on to updating We is forward include to
and focused viral human programs the Our HBV found HBV X% lead always hepatitis. most of on a development is is co-infection clinical severe delta with Hepatitis approximately are in virus, patients. infected form virus delta hepatitis of
orphan However, after progression HDV this delta than liver a hepatitis disease is is HBV hepatitis large an alone. disease in This years delta development FDA XX diagnosis. Eiger of of causes a urgent virus. and virus medical therapy treatments XX% unmet need. pioneering die of within for the much approved space. There US patients with is Europe no more in the Sadly, rapid
patients? HDV We for are progressive win what like devastating asked, a often look rapidly would HDV a disease. is
inflammation has in outcomes. viral lead to been disease, to HDV reduction The to slow reduction load first shown is and which progression therapy of liver goal of in improved
FDA consistent of is this therapies. with Importantly, HDV for development guidance
to and daily improve long-term for lambda, We chronic platform treatment offer HDV compared outcomes programs therapies we in believe peginterferon win are to Additionally, multiple administration dosing. a advancing HDV oral development. that Convenient At an could four critical other the injection, HDV and pass which patients. convenient physicians. to are require both a patients Eiger, that stage compliance will dosing weekly medication, subcutaneous most late and provides lonafarnib, strategy
study and to HDV peginterferon have and study. development to the in D-LIVR oral two in candidates global late-stage patients with the alone peginterferon all across lambda. Phase alfa. for X product oral largest countries. combinations. X and currently the Both is should in benefit patients We in different D-LIVR only with promising are The and HDV, door treatment mechanisms conducted sites well-characterized for XX win HDV a Lonafarnib, over lonafarnib-based dosing in the have deliver regimen lonafarnib is conveniently study combination in HDV be of XXX opens the D-LIVR design administered, Phase action,
are momentum randomized patients randomized. which patients over XX% be are in to expected in to enrolled. We D-LIVR, seek that to date and includes now is pleased continued This screening
are XXXX, track late before to data enrollment end We in for of up pivotal release setting topline on complete XXXX.
in HDV well-tolerated X. Phase which therapy second development Our peginterferon lambda, for a beginning is is interferon,
our with we patient first EMA concurrence of excited single end lambda and begin the this study and expect peginterferon have are LIMT-X HDV an in we FDA and represents study the this We study. in efficient for for called a to pivotal year. approval enroll pathway before to LIMT-X
engaged For clinical a for in hepatitis. over decade, of therapies viral Eiger the development has been
the plus believe gained leader have in a well lambda will positioned for and alone therapies to market that Eiger foundational treatment to lonafarnib be for position of We HDV used care commercial is of billion-dollar opportunity. understanding and them. deep patients need become and the of HDV. combination HDV, a to a in be We peginterferon a
which disorders, how manufacturing designation, for trials plan pipeline. advance as rest in a on future to support We commercial will granted activities the post-bariatric complete has significant been been regulatory plan guidance designation and in we opportunity congenital to well hyperinsulinism, clinical very program. to and as to represents continue FDA Avexitide we year two targeted disease we class as a device HDV, indications. advance disease development of rare pediatric designation. which is hypoglycemia, breakthrough and granted orphan therapy this for therapy first registration Avexitide breakthrough XXXX both novel, therapy rare has our Beyond FDA provide early the different metabolic and enabling as this
Study therapies commercialized serious capital for ultra Phase opportunistically as manner and peginterferon our targeted The placebo-controlled COVID-XX. by of end. TOGETHER re lambda treatment diseases, to sites a We forward While interim across efficient for study a is dosing analysis and reporting could submission data Emergency remain a potential have to for on in patients outpatient convenient results X potentially this explored we year and utility enrolling the focused developing Positive look from rare multiple mission Brazil. Use rare Authorization. clinical support in
the Rare progress Disorders Industry the Organization were Award USA of product. Turning continues very nominee I&D XXXX National Pharmaceutical approved regulatory and to NDA to expect to Zokinvy and Zokinvy first and our of Zokinvy well of XXXX We was approval now ability this the Agent landscapes. Innovation a navigate to launch EMA The and pleased complex Galien year. launch is we Award. later Best Prix has that recipient global demonstrated approval US go from to successfully to for our
orphan have grow established infrastructure along in with and for larger we the scale that future. launches Importantly, commercial across and commercial functions indications medical additional disease affairs can
runway I'd discuss turning and like operations the Phase with million development our XXXX. our planned clinical in detail, to over and fund Before QX more approximately in quarter in to to enough X the Ingrid? Ingrid HDV we sufficient XXX to the cash to studies investments, planned entered call note that fund programs
